Understand the top 10 Pharmaceutical Companies In India Now.

The global pharmaceutical industry is one of the largest and the oldest industries in the world. According to research released by the Quintiles IMS Institute, global spending on medicines is forecast to reach $1.5 trillion by 2021, up 33 percent from 2016 levels,

• Trends Impacting the Global Pharmaceutical Sector
• COVID-19 has impacted health and disease patterns and brought changes to several aspects of the pharmaceutical industry. Some of the emerging trends are highlighted below:
  • Demand for digital transformation
  • Advancements in technology and increasing R&D spends
  • Need for a new understanding of diseases
  • Affordable pricing and improved market access
  • Building a cohesive regulatory framework

Companies often focus their R&D on areas where science is complex and risks of failure are high. Therefore, even though the rapid pace of scientific advances enables a better understanding of diseases at the molecular level, the scientific, technical, and regulatory challenges that come with it create complexities, making drug development difficult
and more time-consuming.

India is one of the important and rapidly growing in the global pharmaceuticals industry. The Indian pharmaceutical industry is the world’s third-largest by volume with annual revenue of about USD41 billion.

It is the largest provider of generic medicines globally, occupying a 20% share in global supply by volume, and also supplies 62% of the global demand for vaccines. The Indian pharma industry has been growing at a compounded annual growth rate (CAGR) of more than 15% over the past five years.

Based on the research and development (R&D) budgets, they can only survive and grow by discovering and developing new drug in Pharma companies.

we can view the list of pharma in India market has placed their performance for the growth of the Indian pharma market.

10. NATCO Pharma Ltd.

• Headquarter: Hyderabad 
• Founded: 1981

NATCO Profile:

Natco Pharma Limited (NATCO) is a vertically integrated, research and development-focused pharmaceutical company engaged in developing manufacturing, and marketing complex products for niche therapeutic areas.

NATCO products comprise Finished Dosage Formulations (FDF), sold in India, the US, and the Rest of the World (RoW) as well as Active Pharmaceutical Ingredients (APIs) that are primarily used for captive consumption in the manufacturing of FDF.

APIs are also sold to customers for various international markets such as Brazil, Europe, and the US. Our API manufacturing capabilities include multi-step synthesis, semi-synthetic fusion technologies,
high-potency APIs, and peptides.

NATCO caters to pharmaceutical companies under select contracts to manufacture and supply pharmaceutical
products. Leveraging our skills and expertise in organic chemistry.

NATCO Product & Manufacturing Units:

• In Pharma
  • 6 Formulations
  • 1 Active ingredients

• Crop Health Sciences
  • 1 Formulations
  • 1 Active ingredients

• NATCO Products
  • In FDF
    • 50+ products in our Oncology and non-oncology business segments.
  • In API
    • 39 active DMFs across therapies such as Central Nervous System, pain management and Cardiovascular care.

NATCO Subsidiaries

• NATCOFARMA DOBRASIL (since 2011),
• NATCO PHARMA CANADA INC. (since 2012),
• NATCO PHARMA Asia Pte. Ltd. (since 2012) and
• NATCO Pharma Australia PTY Ltd.

NATCO R&D

• 40 R&D laboratories in two research and development facilities with a talent pool of over 500 scientists.
• Expenditure of R&D is 1,656 Million

Natco Financial Position:

• Revenue: 20521 Million
• PBT: 5796 Million
• PAT: 4424 Million

9.Torrent Pharmaceuticals Ltd.

• Headquarters: Gujarat, India
• Founded: 1959
• Parent Organization: Torrent Group
• website: www.torrentpharma.com

Torrent Pharmaceutical Profile:

Torrent Pharma is one of the leading pharma companies in India. Torrent Pharma has consistently offered patient-centric pharma solutions through incremental innovations, niche marketing, and specialty focus, establishing itself as a leader and trusted player in the pharmaceutical industry in India.

Torrent has a strong international presence across more than 40 countries with operations in regulated and emerging markets. Torrent Pharma’s business mix (~62% BGx and 38% Gx) is highly optimized.

Torrent Pharma reaches the target market segments through 22 sales divisions with a wide customer coverage through 5000+ stockists and 59000 retailers serviced through 22 distribution centers across India.

Torrent R&D

Torrent Pharma has 8 manufacturing facilities and the R&D Centre at Bhat near Ahmedabad has one of the most advanced infrastructures for both basic and applied research to support all activities related to generic, new drug discovery, API process development, formulation development, and value-added generics.

• Formulation: 2,100 crores+ tabs
• R&D expenditure 2020-21: ₹ 487 crores
• No. of scientists: 700+
• No. of approved ANDA: 100+

Torrent Financial position

• Revenue: 8,005 crores
• EBITDA:2,537 crores
• PBT:1526 crores
• PAT:1252 crores

8.Alkem Laboratories Ltd.

• Headquarter: Mumbai.
• Founded: 1973

Alkem Laboratories Profile:

Alkem Laboratories is one of India’s foremost global pharmaceutical companies. Alkem is engaged in developing, manufacturing, and marketing pharmaceuticals with operational footprints across 40+ countries.

In India, it has a formidable presence in several therapy segments are Anti-infective, gastrointestinal, Pain management, and Vitamin/ Minerals/ Nutrients products.

Alkem Laboratories has consistently ranked amongst the top ten pharmaceutical companies in India, backed
by an extensive portfolio of over 800 brands, vast sales, and distribution network pan-India.

Alkem Laboratories has an infrastructure comprising 21 state-of-the-art manufacturing facilities and six R&D Centres
across India and the US, which are involved in the development of high-quality products. The manufacturing facilities have been approved by the US FDA, World Health Organisation (WHO), MHRA (UK), TGA (Australia), ANVISA (Brazil), and MCC (South Africa).

Aalkem Laboratories Product:

Aalkem Laboratories has a wide range of products spanning multiple Therapeutic Areas (TA) such as Anti-infective, Gastroenterology, Pain Relief/Analgesic, Anti-diabetic, Cardiology, Dermatology, Neurology/Central Nervous System (CNS), and Vitamins, Minerals & Nutrients.

These products are sold in India and internationally and include over 800 brands covering all the major therapeutic segments

Aalkem Laboratories R&D

Aalkem Laboratories has set up 20 manufacturing facilities and 6 R&D centers across multiple locations in India
and the United States. All 6 R&D facilities have been accredited by international regulatory authorities.

• Aalkem Laboratories has invested ₹ 5,322 million.

Aalkem Laboratories Financial Position:

• Revenue: ₹ 88,650 Million
• EBITDA: ₹ 19,424 Million
• PBT: ₹ 18,421 Million
• PAT: ₹ 15,850 Million

7.Biocon Ltd.

• Headquarter: Bengaluru
• Parent Organization: Biocon Group

Biocon Limited is an Indian biopharmaceutical company and also a global leader in fermentation-derived and chemical synthesis-based, high-value APIs. Biocon has successfully built a good track record with leading regulatory agencies worldwide, including the US FDA, EMA, and MHRA. We owe our reputation as a trusted global supplier for APIs.

Biocon product portfolio includes focussed therapies such as Cardiology, Anti-diabetics, Immunosuppressants, Multiple Sclerosis, and Oncology. They have catered to over 1,000 pharmaceutical companies in 100+ countries, including the US, Europe, and other developing countries.

Biocon has also stepped up our efforts to develop new fermentation-derived and chemical synthesis-based molecules, coupled with a focus on peptides and high potent APIs.

Biocon’s strategy is to continue building a differentiated Active Pharmaceutical Ingredients (APIs) portfolio and vertically integrate it where possible to manufacture and supply generic formulations for the global markets. Biocon also continues to explore asset acquisition, external development, and select in-licensing opportunities to bolster our formulation portfolio.

Biocon Financial Position

• Revenue: ₹ 73,603 Million
• R&D expenditure: 6,270 Million
• PBT: ₹ 10,648 Million
• PAT: ₹ 7,405 Million

6.Aurobindo Pharma Ltd.

• Founded: 1986
• Headquarter: Telangana, India.

Aurobindo pharma Profile:

Aurobindo Pharma Limited is a leading global pharmaceutical company, producing generic formulations and Active Pharmaceutical Ingredients (APIs). The Aurobindo pharma growth is aided by cost-effective product development and substantial execution capabilities.

Leverages India’s globally competitive cost base and talented team of scientists to successfully launch affordable products and make them accessible worldwide. It has carved a niche for itself in developing high-quality APIs and
finished dosage forms, especially in regulated markets.

Aurobindo enjoys a presence in 155+ markets and it is an Indian MNC that derives 92% of its revenues from international markets. Our API business has ensured the profitability and growth of our formulations business through seamless vertical integration.

Our API business is supported by technologically advanced research and development infrastructure, which develops new products and plays a role in the delivery of products to the market.

Aurobindo Pharma product portfolio with manufacturing facilities in several countries. Aurobindo has 11 units for APIs / intermediates and 18 units for formulations designed to meet the requirements of both advanced as well as emerging markets.

Aurobindo Pharma R&D

Aurobindo has eight Research and Development (R&D) centers, of which five are in India and three are in the USA. Aurobindo is developing several specialty products in the respiratory and dermatological therapeutic areas, including
metered-dose inhalers (MDIs), dry powder inhalers (DPIs), nasal sprays, topical lotions, creams, ointments, and transdermal patches.

Aurobindo Pharma has invested ₹ 9580 million.

Aurobindo Pharma Financial Position:

• Revenue: ₹ 1,562,218 Lakhs
• PBT: ₹ 419,301 Million
• PAT: ₹ 311,291 Million

5.Cipla Ltd

• Founded: 1935
• Headquarter: Mumbai

Cipla Profile:

Cipla is a global pharmaceutical company focused on the responsible and sustainable growth of complex generics and deepening portfolio in our home markets of India, South Africa, and North America, as well as key regulated and emerging markets.

Cipla has 46 manufacturing sites around the world that produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets.

Cipla has 1500 products in 65 therapeutic categories available in over 50 dosage forms. These capabilities range from the development of a simple molecule to a highly complex multi-chiral centers molecule with a distinction of affordability and highest quality.

R&D Cipla

Cipla is continued to maintain healthy investments in R&D, which helped build a strong growth pipeline for the future. Cipla has six world-class R&D facilities spread across Maharashtra, Karnataka, and New York. They have a highly talented pool of 1,300+ R&D colleagues who are passionate about enhancing Cipla’s intellectual property through innovation and excellence.

Cipla had an investment in R&D with an expenditure of approximately ₹ 6980 crores

Cipla Financial Position

• Revenue: ₹ 18,988.52 Crores
• PBT: ₹ 3,290.06 Crores
• PAT: ₹ 2,388.51 Crores

4.Lupin Ltd

• Founded: 1968
• Headquarter: Mumbai

Lupin Profile

Lupin Limited is an Indian multinational pharmaceutical company based in Mumbai. Our global footprint spans
over a hundred countries and we have world-class operations with a powerful culture of innovation and unyielding integrity.

Lupin is a fully integrated pharmaceutical company is built on the backbone of cutting-edge research, world-class
manufacturing facilities and a truly global supply chain.

Lupin focused on the product portfolio, comprising Generics, Biosimilars, and Specialty Products. Lupin manufactures and markets an extensive variety of branded and generic formulations, Active Pharmaceutical Ingredients (APIs), biotechnology products as well as Over-the-Counter (OTC) medicines across multiple dosage forms and therapeutic categories.

R&D Lupin

Lupin had strengthened the world-class R&D capabilities at our 7 R&D sites. Lupin’s focus will be on increasing the proliferation of their products through our commercial capabilities, driven by marketing offices in 23 countries.

Lupin had invested ₹ 6,276 million

Lupin Financial Position:

• Revenue: 110,559.3 Million
• PBT: 16,297 Million
• PAT: 12,586.2 Million

3. Dr. Reddy’s Laboratories Ltd.

• Founded: 1984
• headquarter: Telugana

Dr. Reddy’s Laboratories Profile:

 Dr. Reddy’s is today a trusted name in the healthcare industry consistently serving the needs of millions of patients with high-quality, affordable, and innovative medicines across therapy areas.

Dr.Reddy is the brand custodian of the Sputnik V vaccine in India and has the sole distribution rights of the first 250 million doses (first and second dose components included) of the vaccine in India.

Dr. Reddy’s strategy is to build a healthy pipeline of differentiated products in relevant therapies including biosimilars and expand Dr. Reddy’s presence in new areas such as nutraceuticals.

Dr. Reddy’s products are available under a brand name, such as Omez (Omeprazole), Nise (Nimesulide), Ketorol Ketorolac Tromethamine), Stamlo (Amlodipine Besylate), Razo (Rabeprazole), among many others.

Dr. Reddy’s R&D Center houses over 70 laboratories and has over 800 research scientists working on various projects. R&D expenses for FY2021 were ₹ 16,541 million.

Dr.Reddy Brand

Dr.Reddy Financial Position

• Revenue: 189.7 billion
• PBT: 26.4 Billion
• PAT: 17.2 billion

2. Sun Pharmaceutical Industries Ltd.

• Founded: 1983
• Headquarter: Mumbai

Sun Pharmaceutical Industries Ltd. (Sun Pharma) is the specialty generic pharmaceutical company in the world. Sun Pharmaceutical manufacture and market a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies.

It includes generics, branded generics, specialty, complex or difficult to make technology-intensive products, over-the-counter (OTC), antiretrovirals (ARVs), Active Pharmaceutical Ingredients (APIs), and Intermediates. Our broad portfolio of more than 2000 high-quality molecules covers multiple dosage forms, including tablets, capsules, injectables, inhalers, ointments, creams, and liquids.

In India with over 8% market share in the domestic market. Sun Pharma’s branded generics business in India commands a leading position in high-growth chronic therapies and strong positioning in the acute segment.

Sun Pharma India specializes in technically complex products, offering a comprehensive therapy basket, and owns over 30brands out of the top 300 pharmaceutical brands in India. The top 10 brands contribute about 18% of India’s revenues. The top therapeutic segments which contribute significantly to the company’s revenue and market share are Neuro-Psychiatry (17%), Gastroenterology (12%), Anti-Infectives (10%), Diabetology (9%), and; Pain/Analgesics (7%) among others. 

Sun Pharmaceutical R&D:

Sun Pharma to develop and market differentiated generics and specialty products globally. The Sun Pharmaceutical
R&D capabilities are supported by best-in-class technologies, helping it deliver affordable products globally.

R&D investments for the year were approximately ₹20 Billion

Sun Pharmaceutical Financial Position:

• Revenue: 331,391.8 Million
• PBT: 27,993.7 Million
• PAT: 22,846.8 Million

1.Glenmark Pharmaceuticals Ltd.

• Founded: 1977
• Headquarter: Mumbai

Glenmark is a leading integrated research-based, a global pharmaceutical company. Glenmark has categorized into 2 types they are,

• Glenmark Life Sciences (GLS), (100% API Subsidiary)
  • GLENMARK LIFE SCIENCES, the API company, is also on a growth trajectory expanding its offerings and tapping new market
• Ichnos Sciences, (100% US based innovation Subsidiary)
  • Ichnos is developing transformative treatments in its focus areas of Oncology and Autoimmune Disease.

Glenmark’s India business further strengthened in its core therapy areas such as Cardiac and Diabetes. As per IQVIA MAT, March 2021, the Cardiac segment market share increased from 4.72% in MAT March 2020 to 4.74%; the Anti-diabetic segment market share increased from 1.71% to 1.85%;

The Antiviral segment market share has increased to 20.1%, and the Derma segment market share changed from 8.89% to 8.57%. Glenmark is ranked 2nd in the overall Dermatology and anti-viral markets, and 6th in the cardiology market in India.

Our branded formulations business in India focuses on high growth and large therapy categories such as dermatology, respiratory, cardiovascular, anti-diabetic, and oncology. We are also present in therapy categories of gynecology, anti-infective, and gastroenterology.

Glenmark R&D & PAT

• Glenmark has 7 Formulation,5 API, and 3 R&D Center.
• R&D expenditure increased to ₹ 29,894.72 mn
• PAT ₹ 35,365 Million which was 10.4% incresed to previous year.